

**Table e-2 – Relative changes and effect sizes for the original cohort**

|  | Relative change |         | Effect size (CI)    |                     |
|--|-----------------|---------|---------------------|---------------------|
|  | STN-DBS         | GPi-DBS | STN-DBS             | GPi-DBS             |
| PDQ SI                                 | -41.2           | -43.2   | 0.94 (0.57 – 1.31)  | 0.94 (0.40 – 1.46)  |
| UPDRS-I                                | -30.9           | -32.7   | 0.33 (0.00 – 0.64)  | 0.44 (-0.04 – 0.90) |
| UPDRS-II                               | -23.4           | -46.8   | 0.61 (0.27 – 0.95)  | 0.82 (0.29 – 1.33)  |
| UPDRS-III                              | -9.2            | -2.8    | 0.27 (-0.04 – 0.59) | 0.06 (-0.38 – 0.50) |
| UPDRS-IV                               | -49.1           | -63.5   | 0.69 (0.34 – 1.04)  | 0.95 (0.39 – 1.48)  |
| H&Y                                    | -0.2            | -7.4    | 0.00 (0.00 – 0.00)  | 0.36 (-0.11 – 0.82) |
| S&E                                    | 7.2             | 8.2     | 1.02 (0.63 – 1.39)  | 0.72 (0.21 – 1.22)  |
| LEDD                                   | -51.3           | -9.7    | 1.30 (0.87 – 1.72)  | 0.23 (-0.22 – 0.67) |
| NMSS                                   | -37.4           | -39.5   | 0.58 (0.24 – 0.91)  | 0.91 (0.38 – 1.43)  |
| Cardiovascular                         | -13.0           | -64.1   | 0.08 (-0.23 – 0.39) | 0.44 (-0.03 – 0.89) |
| Sleep/fatigue                          | -36.9           | -39.7   | 0.55 (0.22 – 0.88)  | 0.82 (0.31 – 1.32)  |
| Mood/cognition                         | -55.9           | -82.3   | 0.34 (0.03 – 0.67)  | 0.82 (0.30 – 1.32)  |
| Perceptual problems/<br>hallucinations | -87.2           | -75.0   | 0.36 (0.04 – 0.68)  | 0.25 (-0.19 – 0.70) |
| Attention/Memory                       | -35.4           | -20.2   | 0.31 (-0.01 – 0.63) | 0.21 (-0.24 – 0.65) |
| Gastrointestinal                       | 2.7             | -1.1    | 0.03 (-0.28 – 0.34) | 0.01 (-0.42 – 0.43) |
| Urinary                                | -30.2           | -5.9    | 0.29 (-0.03 – 0.60) | 0.06 (-0.38 – 0.50) |
| Sexual function                        | -48.5           | -49.6   | 0.38 (0.05 – 0.70)  | 0.64 (0.15 – 1.12)  |
| Miscellaneous                          | -41.4           | -18.4   | 0.52 (0.19 – 0.85)  | 0.22 (-0.23 – 0.66) |

**Abbreviations:** **CI** = confidence interval; **ES** = effect size; **GPi-DBS** = Pallidal stimulation; **H&Y** = Hoehn and Yahr Scale, **LEDD** = levodopa equivalent daily dose; **NMSS** = Non-motor Symptom Scale; **PDQ SI** = Parkinson's Disease Questionnaire Summary Index; **RC** = relative change; **S&E** = Schwab and England Scale; **STN-DBS** = Subthalamic stimulation; **UPDRS-I, -II, -III, and -IV** = Unified Parkinson's Disease Rating Scale-cognition, -activities of daily living, -motor impairment, and -motor complications.

RC = (mean Test<sub>follow-up</sub> – mean Test<sub>baseline</sub>) / Test<sub>baseline</sub>

ES = (mean Test<sub>baseline</sub> – mean Test<sub>follow-up</sub>) / SD Test<sub>change score</sub>

ES: 'small' (0.20-0.49), 'moderate' (0.50-0.79), and 'large' ( $\geq 0.80$ )